Suppr超能文献

不可手术切除的唾液腺肿瘤的中子与光子照射:一项美国放射肿瘤学组-英国医学研究委员会合作随机研究的结果

Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study.

作者信息

Griffin T W, Pajak T F, Laramore G E, Duncan W, Richter M P, Hendrickson F R, Maor M H

机构信息

Department of Radiation Oncology, University of Washington Hospital/School of Medicine, Seattle 98195.

出版信息

Int J Radiat Oncol Biol Phys. 1988 Nov;15(5):1085-90. doi: 10.1016/0360-3016(88)90188-5.

Abstract

A total of 32 patients with inoperable, recurrent or unresectable malignant salivary gland tumors were entered on a randomized RTOG/MRC study comparing fast neutron radiotherapy with conventional photon radiotherapy. Twenty-five patients were entered from the United States and 7 patients were entered from Scotland. Seventeen patients were randomized to receive neutrons and 15 patients were randomized to receive photons. Sixty-one percent of the neutron-treated patients and 75% of the photon-treated patients presented with inoperable or unresectable tumors, while 39% of the neutron-treated and 25% of the photon-treated patients had recurrent disease. Twenty-five patients were study-eligible and analyzable. The minimum follow-up time is 2 years. The complete tumor clearance rates at the primary site were 85% (11/13) for neutrons and 33% (4/12) for photons following protocol treatment (p = 0.01). The complete tumor clearance rates in the cervical lymph nodes were 86% (6/7) for neutrons and 25% (1/4) for photons. The overall loco/regional complete tumor response rates were 85% and 33% for neutrons and photons respectively. The loco/regional control rates at 2 years for the 2 groups are 67% for neutrons and 17% for photons (p less than 0.005). The 2-year survival rates are 62% and 25% for neutrons and photons respectively (p = 0.10). These findings are consistent with previously published uncontrolled series.

摘要

共有32例无法手术、复发或不可切除的恶性唾液腺肿瘤患者参加了一项RTOG/MRC随机研究,比较快中子放疗与传统光子放疗。25例患者来自美国,7例患者来自苏格兰。17例患者被随机分配接受中子放疗,15例患者被随机分配接受光子放疗。接受中子治疗的患者中有61%以及接受光子治疗的患者中有75%表现为无法手术或不可切除的肿瘤,而接受中子治疗的患者中有39%以及接受光子治疗的患者中有25%患有复发性疾病。25例患者符合研究条件且可进行分析。最短随访时间为2年。按照方案治疗后,原发部位的肿瘤完全清除率中子组为85%(11/13),光子组为33%(4/12)(p = 0.01)。颈部淋巴结的肿瘤完全清除率中子组为86%(6/7),光子组为25%(1/4)。中子组和光子组的局部/区域肿瘤总体完全缓解率分别为85%和33%。两组2年时的局部/区域控制率中子组为67%,光子组为17%(p<0.005)。中子组和光子组的2年生存率分别为62%和25%(p = 0.10)。这些发现与之前发表的非对照系列研究结果一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验